Balaisyte; Joos; Hiligsmann (2018BALAISYTE, L.; JOOS, A.; HILIGSMANN, M. Early dialogue in Europe: perspectives on value, challenges, and continuing evolution. International Journal of Technology Assessment in Health Care, Cambridge, v. 34, n. 5, p. 514-518, 2018. DOI: 10.1017/S0266462318000545 https://doi.org/10.1017/S026646231800054...
) |
European Union |
EMA and HTA agencies |
Reimbursement |
Early dialogue |
Battista et al (1999BATTISTA, R. N. Health technology assessment and the regulation of medical devices and procedures in Quebec. Synergy, collusion, or collision? International Journal of Technology Assessment in Health Care, Cambridge, v. 15, n. 3, p. 593-601, 1999.) |
Canada |
CETS and regulation |
Incorporation |
Not specified |
Berntgen et al (2014)BERNTGEN, M. et al. Improving the contribution of regulatory assessment reports to health technology assessments: a collaboration between the European medicines agency and the European network for health technology assessment. Value in Health, Amsterdam, v. 17, p. 634-641. DOI: 10.1016/j.jval.2014.04.006 https://doi.org/10.1016/j.jval.2014.04.0...
|
European Union |
EUnetHTA |
Marketing authorizations |
Early dialogue Scientific Advice |
Henshall et al (2011HENSHALL, C. Interactions between health technology assessment, coverage, and regulatory processes: emerging issues, goals, and opportunities. International Journal of Technology Assessment in Health Care, Cambridge, v. 27, n. 3, p. 253-260, 2011. DOI: 10.1017/s0266462311000262 https://doi.org/10.1017/s026646231100026...
) |
European Union |
Not shown |
Regulatory approval and coverage |
Early dialogue Scientific Advice Risk sharing or managed entry |
Cuche et al (2014CUCHE, M. et al. Early dialogue with health technology assessment bodies: a european perspective. International Journal of Technology Assessment in Health Care, Cambridge, v. 30, n. 6, p. 571-578, 2014. https://doi.org/10.1017/s0266462314000713 https://doi.org/10.1017/s026646231400071...
) |
European Union |
EUnetHTA |
Pricing and reimbursement process |
Early dialogue |
Facey et al (2015FACEY, K.; HENSHALL, C.; SAMPIETRO-COLOM, L.; THOMAS, S. Improving the effectiveness and efficiency of evidence production for health technology assessment. International Journal of Technology Assessment in Health Care, Cambridge, v. 31, n. 4, p. 201-206, 2015. DOI: 10.1017/s0266462315000355 https://doi.org/10.1017/s026646231500035...
) |
Not shown |
HTAi |
Not shown |
Early dialogue |
Forrester et al (1997FORRESTER, J. S.; TOPOL, E. J.; ABELE, J. E.; HOLMES, D. R. J.; SKORTON, D. J. Task force 5: Assessment, approval, and regulation of new technology. Journal of the American College of Cardiology, Amsterdam, v. 29, n. 6, p. 1171-1179, 1997. DOI: 10.1016/s0735-1097(97)82752-0 https://doi.org/10.1016/s0735-1097(97)82...
) |
U.S. |
FDA |
Marketing authorizations and post-market monitoring |
Early Dialogue |
Frønsdal et al (2012FRØNSDAL, K. et al. Interaction initiatives between regulatory, health technology assessment and coverage bodies, and industry. International Journal of Technology Assessment in Health Care, Cambridge, v. 28, n. 4, p. 374-381, 2012. DOI: 10.1017/s0266462312000591 https://doi.org/10.1017/s026646231200059...
) |
Australia, Canada, European Union |
HTAi and CIRS Policy Forum. Collaboration on EPAR content (EUnetHTA and EMA) |
Regulatory approval and coverage |
Scientific advice Parallel submissions Information sharing Parallel advice Parallel review of medical devices |
Henshall et al (2014HENSHALL, C. et al. Understanding the role and evidence expectations of health technology assessment and coverage/payer bodies: what are they looking for, and how and why does this differ from what regulators require? Therapeutic Innovation & Regulatory Science, London, v. 48, n. 3, p. 341-346, 2014. DOI: 10.1177/2168479013512488 https://doi.org/10.1177/2168479013512488...
) |
UK |
HTAi |
Not shown |
Early dialogue |
Cox; de Pouvourville (2015COX, J. L.; POUVOURVILLE, G. Achieving access: addressing the needs of payors and health technology assessment agencies. European Heart Journal, Oxford, v. 17, supl. D, D15-20, 2015. DOI: 10.1093/eurheartj/suv041 https://doi.org/10.1093/eurheartj/suv041...
) |
European Union |
EMA and HTA agencies |
Reimbursement |
Real world evidence Risk sharing or managed entry |
Drummond (2015DRUMMOND, M. Health technology assessment and its interface with regulation, policy and management. In: LLANO-SEÑARÍS, J. C.; CAMPILLO-ARTERO, C. Health Technology Assessment and health policy today: a multifaceted view of their unstable crossroads. London: Springer International Publishing, 2015. p. 3-14.) |
Sweden |
EUNetHTA |
Regulatory approval and coverage |
Early dialogue Parallel advice |
Maignen et al (2017MAIGNEN, F. Integrating health technology assessment requirements in the clinical development of medicines: the experience from NICE scientific advice. European Journal of Clinical Pharmacology, Berlin, v. 73, n. 3, p. 297-305, 2017. DOI: 10.1007/s00228-016-2174-2 https://doi.org/10.1007/s00228-016-2174-...
) |
European Union |
NICE and EMA |
Not shown |
Parallel advice Scientific advice |
McAuslane; Liberti; Connelly (2019)MCAUSLANE, N.; LIBERTI, L.; CONNELLY, P. The confluence of accelerated regulatory and Health Technology Assessment access pathways. Clinical Pharmacology & Therapeutics, Hoboken, v. 105, n. 4, p. 935-942, 2019. DOI: 10.1002/cpt.1315 https://doi.org/10.1002/cpt.1315...
|
U.S. |
CIRS |
Not shown |
Flexible access and reimbursement pathways Early dialogue |
Tafuri et al (2018TAFURI, G. et al. The impact of parallel regulatory-health technology assessment scientific advice on clinical development. Assessing the uptake of regulatory and health technology assessment recommendations. British Journal of Clinical Pharmacology, London, v. 84, n. 5, p. 1013-1019, 2018. DOI: 10.1111/bcp.13524 https://doi.org/10.1111/bcp.13524...
) |
European Union |
EUnetHTA /EMA |
Not shown |
Scientific advice |
Tafuri et al (2016TAFURI, G. et al. How aligned are the perspectives of EU regulators and HTA bodies? A comparative analysis of regulatory-HTA parallel scientific advice. British Journal of Clinical Pharmacology, London, v. 82, p. 965-973, 2016. DOI: 10.1111/bcp.13023 https://doi.org/10.1111/bcp.13023...
) |
European Union |
EMA and HTA agencies |
Not shown |
Scientific advice |
Tsoi (2013TSOI, B. et al. Harmonization of reimbursement and regulatory approval processes: a systematic review of international experiences. Expert Review of Pharmacoeconomics & Outcomes Research, London, v. 13 n. 4, p. 497-511, 2013. DOI: 10.1586/14737167.2013.814962 https://doi.org/10.1586/14737167.2013.81...
) |
Canada |
CADTH, HQO, INESSS, Alberta Health and Wellness |
Regulatory approval and coverage |
Harmonization of HTA-reimbursement and regulatory activities |
Vella Bonanno et al (2019)VELLA BONANNO, P. et al. Proposal for a regulation on health technology assessment in Europe - opinions of policy makers, payers and academics from the field of HTA. Expert Review of Pharmacoeconomics & Outcomes Research, London, v. 19, n. 3, p. 251-261, 2019. DOI: 10.1080/14737167.2019.1575730 https://doi.org/10.1080/14737167.2019.15...
|
European Union |
EUnetHTA |
Pricing and reimbursement process |
Real world evidence Scientific advice |
Wang et al (2018WANG, T. Building synergy between regulatory and hta agencies beyond processes and procedures-can we effectively align the evidentiary requirements? A survey of stakeholder perceptions., Amsterdam, v. 21, n. 6, p. 707-714, 2018. DOI: 10.1016/j.jval.2017.11.003 https://doi.org/10.1016/j.jval.2017.11.0...
) |
European Union |
TLV, NICE, OSTEBA, EMA, IMB, MEB and MPA |
Pricing and reimbursement process |
Scientific advice Information sharing |
Wonder et al (2013WONDER, M.; BACKHOUSE, M. E.; HORNBY, E. Early scientific advice obtained simultaneously from regulators and payers: findings from a pilot study in Australia. Value in Health, Amsterdam, v. 16, n. 6, p. 1067-1073, 2013. DOI: https://doi.org/10.1016/j.jval.2013.07.007 https://doi.org/10.1016/j.jval.2013.07.0...
) |
Australia |
TGA and PBAC |
Pricing and reimbursement process |
Early dialogue |